EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

SMC3 Is Highly Expressed in Gliomas and Is Associated With Favorable Prognosis and B Cell–Related Immune Features

Wei Han, Lei Tian, Haonan Li, Yadong Liu, Xuetao Han, Liubing Hou, Zhiqing Xiao, Xiaoying Xue iD, Huandi Zhou iD

Technology in Cancer Research & Treatment · 2026-05 · 25

DOI: 10.1177/15330338261454517 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 27.05.2026. Verfasst von Wei Han und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, The Second Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Glioma, Cell Cycle Proteins, B-Lymphocytes, Chromosomal Proteins, Non-Histone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hebei Province Medical-Research-Enterprise Joint Innovation Special Project Program, the Medical Science Research Project of Health Commission of Hebei Province, the Youth Natural Science Foundation of Hebei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

SMC3, a core component of the cohesin complex, plays diverse roles in tumorigenesis across different cancer types. However, its expression pattern, prognostic significance, and potential association with the immune microenvironment in gliomas remain largely unexplored.

Methods

In this retrospective study, we systematically analyzed SMC3 expression using multiple transcriptomic datasets, including CGGA (CGGA-325, CGGA-301), TCGA, and GEO (GSE4290, GSE50161), and validated protein-level expression in 44 clinical glioma specimens via immunohistochemistry. Associations with overall survival (OS) were assessed using Kaplan–Meier and Cox regression analyses. Immune microenvironment features were evaluated using ESTIMATE and TIMER2.0, and pathway enrichment was analyzed through GSEA. Core B cell–related genes and signaling pathways associated with SMC3 were further identified by intersecting SMC3-correlated genes with MSigDB C7 and KEGG B cell receptor signaling gene sets.

Results

SMC3 was significantly overexpressed in glioma tissues compared with normal brain, with higher expression in lower-grade gliomas (LGG) than glioblastoma (GBM). High SMC3 expression was associated with prolonged OS across CGGA-325, CGGA-301, and the Validation Cohort, and remained prognostically favorable in specific clinical subgroups, including MGMT-unmethylated and 1p/19q non-codeleted tumors. SMC3 high-expression tumors exhibited lower overall immune and stromal scores but showed significant positive correlations with B cell and plasma cell infiltration. GSEA revealed enrichment of PI3K–AKT–MYC– and MTORC1-related pathways in high SMC3 tumors. Intersection analyses identified four core B cell–related genes (AKT3, CHUK, GSK3B, PIK3CA) within the PI3K–Akt signaling pathway, suggesting SMC3 expression may be associated with B cell–related immune features.

Conclusions

SMC3 is highly expressed in gliomas and is associated with favorable prognosis. Its expression correlates with B cell–related immune infiltration and activation of PI3K–Akt–MYC signaling, highlighting a potential role in shaping local immune microenvironments. These findings provide novel evidence for SMC3 as a prognostic biomarker and suggest a potential association with B cell–mediated immune features in gliomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaCell Cycle ProteinsB-LymphocytesChromosomal Proteins, Non-HistoneBiomarkers, TumorBrain NeoplasmsHumansPrognosisTumor MicroenvironmentFemaleGene Expression Regulation, NeoplasticMaleGene Expression ProfilingSignal TransductionMiddle AgedKaplan-Meier EstimateNeoplasm GradingChondroitin Sulfate Proteoglycans

Stichwörter der Autor:innen

B cellsPI3K–akt signalingSMC3gliomaprognosistumor immune microenvironment

Substanzen

Cell Cycle ProteinsChromosomal Proteins, Non-HistoneBiomarkers, TumorSMC3 protein, humanChondroitin Sulfate Proteoglycans

Autor:innen und Institutionen

  • Department of Radiotherapy, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
  • Department of Oncology, Hebei General Hospital, Shijiazhuang, China.

ORCID-Profile: Xiaoying Xue, Huandi Zhou

Förderung

  • Hebei Province Medical-Research-Enterprise Joint Innovation Special Project Program
  • the Medical Science Research Project of Health Commission of Hebei Province
  • the Youth Natural Science Foundation of Hebei Province

Zitieren

APA

Han, W., Tian, L., Li, H., Liu, Y., Han, X., Hou, L., Xiao, Z., Xue, X., & Zhou, H. (2026). SMC3 Is Highly Expressed in Gliomas and Is Associated With Favorable Prognosis and B Cell–Related Immune Features. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261454517

Vancouver

Han W, Tian L, Li H, Liu Y, Han X, Hou L, et al. SMC3 Is Highly Expressed in Gliomas and Is Associated With Favorable Prognosis and B Cell–Related Immune Features. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261454517

BibTeX
@article{Han2026,
  author = {Han, Wei and Tian, Lei and Li, Haonan and Liu, Yadong and Han, Xuetao and Hou, Liubing and Xiao, Zhiqing and Xue, Xiaoying and Zhou, Huandi},
  title = {SMC3 Is Highly Expressed in Gliomas and Is Associated With Favorable Prognosis and B Cell–Related Immune Features},
  journal = {Technology in Cancer Research & Treatment},
  year = {2026},
  volume = {25},
  doi = {10.1177/15330338261454517}
}
Kostenlos starten →